Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Circulation

• Publication date

  2015-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.114.013887PMID 25411157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neprilysin inhibitors preserve renal function in heart failure.

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  2015cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer’s Disease

  2013cited by this paper
• Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

  2006cited by this paper
• Losartan Increases Bradykinin Levels in Hypertensive Humans

  2005cited by this paper
• Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406

  2005cited by this paper
• Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

  2004cited by this paper
• Vasopeptidase inhibition and angio-oedema.

  2000cited by this paper

• Effect of low blood pressure on prognosis of acute heart failure

  2024cites this paper
• Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists

  2023cites this paper
• Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication

  2021cites this paper
• Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats

  2019cites this paper
• How does neprilysin inhibition in heart failure work?

  2019cites this paper
• Exercise monitoring of young adults using a Facebook application

  2017cites this paper
• New Pharmacological Strategies to Increase cGMP.

  2016cites this paper
• Making Education Easy Sacubitril / Valsartan ( Entresto ® ) PRODUCT

  2016cites this paper
• Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use

  2015cites this paper
• An update of the blockade of the renin angiotensin aldosterone system in clinical practice

  2015cites this paper
• Therapeutic developments in the therapy of heart failure: lessons to be learned.

  2015cites this paper
• Achieving optimal doses in treatment of heart failure with reduced ejection fraction at Nhan dan Gia Dinh Hospital

  year unknowncites this paper